期刊
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
卷 11, 期 6, 页码 543-548出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152011796011109
关键词
Glypican-3; Hepatocellular Carcinoma; therapeutic antibody; peptide vaccine; immunohistochemistry; oncofetal protein; Wnt signaling
Glypican-3 (GPC3) is a developmentally-regulated oncofetal protein that has been established as a clinically-relevant biomarker for early hepatocellular carcinoma (HCC). It is one of the first transcripts to appear during malignant hepatocyte transformation, and is expressed at the protein level in approximately half of high-grade dysplastic macronodules in cirrhotic liver. Several studies show it is expressed in most (75 to 100%) of HCCs confirmed by histopathology. The protein is anchored to the hepatocyte membrane by a glycosyl-phosphatidylinositol (GPI) anchor and shows consistent membrane immunostaining pattern, making it a viable target for immunotherapeutic approaches. Targeting GPC3 for therapeutic intervention is a promising approach for the clinical management of HCC and selected other tumors that express the marker.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据